复星医药(600196.SH)：控股子公司药品斯鲁利单抗注射液注册申请获受理

Core Viewpoint - Fosun Pharma's subsidiary Shanghai Fuhong Hanlin Biotech has received acceptance from the National Medical Products Administration for a new indication of the drug Surulitinib Injection, which is now included in the priority review process [1] Group 1 - The new indication is for the use of Surulitinib Injection in combination with platinum-based chemotherapy as neoadjuvant therapy and postoperative adjuvant treatment for PD-L1 positive, resectable gastric cancer patients [1] - Surulitinib is an innovative anti-PD-1 monoclonal antibody independently developed by the group [1]